SCHEMBL20134845

SCHEMBL20134845

COc1cc(C(=O)O)c(F)cc1C(=O)C(C)C

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.45
FYN P06241 1/20 0.45
KDM4E B2RXH2 5/20 0.42
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
MAPK1 P28482 2/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
FABP4 P15090 1/20 0.39
MYC P01106 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CYP3A4 P08684 1/20 0.39
PYGL P06737 1/20 0.38
PKM P14618 1/20 0.38
MEN1 O00255 1/20 0.38
GFER P55789 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135416 0.86 KDM4E (0.46) KDM4EALDH1A1HPGDMAPK1HTT
SCHEMBL1766160 0.81 LCK (0.60) LCKFYNKDM4EALDH1A1HPGD
SCHEMBL29688792 0.81 LCK (0.45) LCKFYNKDM4EALDH1A1HPGD
SCHEMBL20135679 0.81 LCK (0.45) LCKFYNKDM4EALDH1A1HPGD
SCHEMBL18700941 0.79 HTT (0.55) LCKFYNKDM4EALDH1A1HPGD
SCHEMBL17700509 0.79 HTT (0.55) LCKFYNKDM4EALDH1A1HPGD
SCHEMBL70549 0.77 LCK (0.49) LCKFYNKDM4EALDH1A1HPGD
SCHEMBL1931203 0.77 ALDH1A1 (0.56) LCKFYNKDM4EALDH1A1HPGD
SCHEMBL21274816 0.76 LCK (0.50) LCKFYNKDM4EALDH1A1HPGD
SCHEMBL1263693 0.76 LCK (0.50) LCKFYNKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 LCK 2962/4885FYN 3198/4885KDM4E 725/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 LCK 2430/4885FYN 3132/4885KDM4E 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.